Trial Profile
A Phase 2 Multi-center Investigation of Efficacy of ABI-009 (Nab-sirolimus) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Perivascular epithelioid cell tumours
- Focus Registrational; Therapeutic Use
- Acronyms AMPECT
- Sponsors AADi
- 17 Mar 2024 Results presented in an Aadi media release.
- 17 Mar 2024 According to an Aadi media release, new subgroup analysis will be presented during an oral plenary at the Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, CA on March 17, 2024.
- 01 Mar 2024 Results published in an Aadi media release.